These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38775250)

  • 1. Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of the digestive system.
    Tao Z; Chen Z; Gao Y; Quan M
    Cancer Rep (Hoboken); 2024 May; 7(5):e2100. PubMed ID: 38775250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer].
    Li XQ; Zhao ZL; Hou ML; Cui YX; Han SY; Fu FF
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1292-1297. PubMed ID: 34915639
    [No Abstract]   [Full Text] [Related]  

  • 3. Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.
    Miyawaki T; Naito T; Doshita K; Kodama H; Mori M; Nishioka N; Iida Y; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Kenmotsu H; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
    Thorac Cancer; 2022 Jul; 13(14):2064-2074. PubMed ID: 35698259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of the cachexia index in patients with small cell lung cancer.
    Go SI; Park MJ; Lee GW
    BMC Cancer; 2021 May; 21(1):563. PubMed ID: 34001060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
    Jo H; Yoshida T; Horinouchi H; Yagishita S; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Takahashi K; Motoi N; Ohe Y
    Cancer Immunol Immunother; 2022 Feb; 71(2):387-398. PubMed ID: 34180007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
    Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
    Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
    Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
    [No Abstract]   [Full Text] [Related]  

  • 8. Hand grip strength-based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer.
    Xie H; Ruan G; Wei L; Zhang H; Ge Y; Zhang Q; Lin S; Song M; Zhang X; Liu X; Li X; Zhang K; Yang M; Tang M; Song CH; Gan J; Shi HP
    J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):382-390. PubMed ID: 36447437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
    Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
    Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia.
    Xie HL; Ruan GT; Wei L; Zhang Q; Ge YZ; Song MM; Zhang X; Lin SQ; Liu XY; Zhang XW; Li XR; Zhang KP; Hu CL; Yang M; Tang M; Song CH; Cong MH; Weng M; Li ZN; Li W; Wang KH; Shi HP
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):879-890. PubMed ID: 36872512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive evaluation of serum hepatic proteins in predicting prognosis among cancer patients with cachexia: an observational cohort study.
    Huang JX; Zhang X; Tang M; Zhang Q; Deng L; Song CH; Li W; Shi HP; Cong MH
    BMC Cancer; 2024 Mar; 24(1):293. PubMed ID: 38438901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
    Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a cancer cachexia risk score for digestive tract cancer patients before abdominal surgery.
    Tan S; Xu J; Wang J; Zhang Z; Li S; Yan M; Tang M; Liu H; Zhuang Q; Xi Q; Meng Q; Jiang Y; Wu G
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):891-902. PubMed ID: 36880286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.
    Goh MJ; Kang W; Jeong WK; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Sci Rep; 2022 May; 12(1):7647. PubMed ID: 35538112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Matsuo N; Azuma K; Murotani K; Murata D; Matama G; Kawahara A; Kojima T; Tokito T; Hoshino T
    Thorac Cancer; 2023 May; 14(15):1362-1367. PubMed ID: 37037511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
    Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
    Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma.
    Go SI; Park MJ; Park S; Kang MH; Kim HG; Kang JH; Kim JH; Lee GW
    J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2211-2219. PubMed ID: 34676685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
    Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
    Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.